Saturday March 23, 2019

Harnessing sperm may help fight cervical cancer

0
//
Harnessing sperm may help fight cervical cancer
Scientists report that they have exploited the swimming power of sperms to ferry a cancer drug directly to a cervical tumour in lab tests. wikimedia commons

London, Dec 25, 2017: German researchers have developed a new chemotherapy drug delivery system that arms sperm with powerful drugs to attack cervical cancer tumours. Scientists, from the Leibniz Institute for Solid State and Materials Research, report that they have exploited the swimming power of sperms to ferry a cancer drug directly to a cervical tumour in lab tests.

In the study, the team led by Mariana Medina-Sanchez from the varsity, packaged a common cancer drug, doxorubicin, into bovine sperm cells and outfitted them with tiny magnetic harnesses. Using a magnetic field, a sperm-hybrid motor was guided to a lab-grown tumour of cervical cancer cells. When the harness arms pressed against the tumour, the arms opened up, releasing the sperm.

The sperm then swam into the tumour, fused its membrane with that of a cancer cell, and released the drug. When unleashed by the thousands, the drug-loaded sperm killed more than 80 per cent of a cancerous ball while leaking very little of their payload in the process.The new findings, detailed in the journal ACS Nano, could pave the way for applications outside of chemo delivery for cervical cancer patients.

However, further work is needed to ensure the system could work in animals and eventually humans, but researchers say the sperm motors have the potential to one day treat cancer and other diseases in the female reproductive tract, such as the endometriosis or ectopic pregnancies.

German researchers have developed a new chemotherapy drug delivery system that arms sperm with powerful drugs to attack cervical cancer tumours.Scientists, from the Leibniz Institute for Solid State and Materials Research, report that they have exploited the swimming power of sperms to ferry a cancer drug directly to a cervical tumour in lab tests.

In the study, the team led by Mariana Medina-Sanchez from the varsity, packaged a common cancer drug, doxorubicin, into bovine sperm cells and outfitted them with tiny magnetic harnesses. Using a magnetic field, a sperm-hybrid motor was guided to a lab-grown tumour of cervical cancer cells. When the harness arms pressed against the tumour, the arms opened up, releasing the sperm.

The sperm then swam into the tumour, fused its membrane with that of a cancer cell, and released the drug. When unleashed by the thousands, the drug-loaded sperm killed more than 80 per cent of a cancerous ball while leaking very little of their payload in the process.The new findings, detailed in the journal ACS Nano, could pave the way for applications outside of chemo delivery for cervical cancer patients.

However, further work is needed to ensure the system could work in animals and eventually humans, but researchers say the sperm motors have the potential to one day treat cancer and other diseases in the female reproductive tract, such as the endometriosis or ectopic pregnancies. (IANS)

Next Story

Risk of Cervical Cancer Highest in Middle-aged Indian Women

" While PAP test is much more likely to miss precancerous cervical disease, HPV testing is more sensitive for detecting localised infection and marginally less sensitive for distant infection," Das noted

0
Cancer
Cancer Ribbon. Pixabay

Nearly 50 per cent of middle-aged women in India were found to have positive cases of high-risk human papillomavirus (HPV) — the main risk factor for cervical cancer, says a report from SRL Diagnostics.

Human papilloma virus (HPV) is a group of viruses that are extremely common worldwide. There are more than 100 types of HPV, of which at least 14 are cancer-causing (also known as high risk type).

The virus is mainly transmitted through sexual contact and most people are infected with HPV shortly after the onset of sexual activity.

Two HPV types (16 and 18) cause 70 per cent of cervical cancers and precancerous cervical lesions.

Analysis of HPV test reports of 4,500 women pan-India between 2014 and 2018, showed that women aged between 31 and 45 years had the highest percentage of high-risk HPV at 47 per cent.

This was followed by 30 per cent of women aged between 16 and 30 years being affected by the risk.

Cancer survivor, flickr

Cervical cancer accounts for one-third of all global deaths, with 74,000 deaths occurring annually and is the second leading cause of cancer deaths among women in India.

However, “cervical cancer is also the only cancer which is preventable if care is taken in the initial stage”, said B.R Das from SRL Diagnostics in a statement issued here on Saturday.

“The high mortality rate from cervical cancer globally could be reduced through a comprehensive approach that includes screening, early diagnosis and treatment programmes,” he added.

Also Read- Premature to Say Social Media Use Leads to Depression

Besides vaccination before girls become sexually active, secondary prevention can be done by regular cervical smear of PAP smear which can pick up any abnormal cells in the cervix before they become cancerous.

“While PAP test is much more likely to miss precancerous cervical disease, HPV testing is more sensitive for detecting localised infection and marginally less sensitive for distant infection,” Das noted. (IANS)